WO2021236672A3 - Compositions and methods for prevention of coronavirus infection - Google Patents

Compositions and methods for prevention of coronavirus infection Download PDF

Info

Publication number
WO2021236672A3
WO2021236672A3 PCT/US2021/033009 US2021033009W WO2021236672A3 WO 2021236672 A3 WO2021236672 A3 WO 2021236672A3 US 2021033009 W US2021033009 W US 2021033009W WO 2021236672 A3 WO2021236672 A3 WO 2021236672A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prevention
compositions
coronavirus infection
polypeptides
Prior art date
Application number
PCT/US2021/033009
Other languages
French (fr)
Other versions
WO2021236672A2 (en
Inventor
Kenneth E. Palmer
Joshua L. FUQUA
Lisa Cencia ROHAN
Lin Wang
Barry R. O'keefe
Original Assignee
University Of Louisville Research Foundation, Inc.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Louisville Research Foundation, Inc., University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Louisville Research Foundation, Inc.
Priority to US17/999,235 priority Critical patent/US20230218715A1/en
Priority to CA3179307A priority patent/CA3179307A1/en
Priority to AU2021276335A priority patent/AU2021276335A1/en
Priority to EP21809656.8A priority patent/EP4153609A4/en
Publication of WO2021236672A2 publication Critical patent/WO2021236672A2/en
Publication of WO2021236672A3 publication Critical patent/WO2021236672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to griffithsin polypeptides and methods of using the same in inhibition of viral infection. Certain embodiments of the present invention relate to modified griffithsin polypeptides and methods of inhibiting coronavirus infection in a host by administering modified griffithsin polypeptides to the upper respiratory tract of the host. Further embodiments relate to an intranasal spray formulation including griffithsin polypeptides in a composition including a preservative and a viscosity modifier.
PCT/US2021/033009 2020-05-18 2021-05-18 Compositions and methods for prevention of coronavirus infection WO2021236672A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/999,235 US20230218715A1 (en) 2020-05-18 2021-05-18 Compositions and methods for prevention of coronavirus infection
CA3179307A CA3179307A1 (en) 2020-05-18 2021-05-18 Compositions and methods for prevention of coronavirus infection
AU2021276335A AU2021276335A1 (en) 2020-05-18 2021-05-18 Compositions and methods for prevention of Coronavirus infection
EP21809656.8A EP4153609A4 (en) 2020-05-18 2021-05-18 Compositions and methods for prevention of coronavirus infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063026375P 2020-05-18 2020-05-18
US63/026,375 2020-05-18
US202063070375P 2020-08-26 2020-08-26
US63/070,375 2020-08-26

Publications (2)

Publication Number Publication Date
WO2021236672A2 WO2021236672A2 (en) 2021-11-25
WO2021236672A3 true WO2021236672A3 (en) 2021-12-16

Family

ID=78707548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/033009 WO2021236672A2 (en) 2020-05-18 2021-05-18 Compositions and methods for prevention of coronavirus infection

Country Status (5)

Country Link
US (1) US20230218715A1 (en)
EP (1) EP4153609A4 (en)
AU (1) AU2021276335A1 (en)
CA (1) CA3179307A1 (en)
WO (1) WO2021236672A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243843A1 (en) * 2021-05-20 2022-11-24 Council For Scientific And Industrial Research Antiviral lotion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201779A1 (en) * 2008-08-26 2012-08-09 Trutek Corporation Antihistamine and antihistamine-like nasal application, products
US20170239220A1 (en) * 2014-06-10 2017-08-24 Nasaleze Patents Limited Improvements to Nasal Compositions and Method of Use Thereof
US20200087359A1 (en) * 2015-02-10 2020-03-19 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Griffithsin mutants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311532A1 (en) * 2005-12-01 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-viral griffithsin compounds, compositions, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201779A1 (en) * 2008-08-26 2012-08-09 Trutek Corporation Antihistamine and antihistamine-like nasal application, products
US20170239220A1 (en) * 2014-06-10 2017-08-24 Nasaleze Patents Limited Improvements to Nasal Compositions and Method of Use Thereof
US20200087359A1 (en) * 2015-02-10 2020-03-19 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Griffithsin mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIA ET AL.: "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan- coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion", CELL RES, vol. 30, no. 4, April 2020 (2020-04-01), pages 343 - 355, XP037082964, DOI: 10.1038/s41422-020-0305-x *

Also Published As

Publication number Publication date
CA3179307A1 (en) 2021-11-25
WO2021236672A2 (en) 2021-11-25
EP4153609A4 (en) 2024-05-22
AU2021276335A1 (en) 2023-01-19
US20230218715A1 (en) 2023-07-13
EP4153609A2 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
MX2022013270A (en) Antiviral application of nucleoside analog or combination formulation containing nucleoside analog.
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
MX2024003960A (en) Nitrile-containing antiviral compounds.
WO2021236672A3 (en) Compositions and methods for prevention of coronavirus infection
MX2022014561A (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm.
MX2023006504A (en) Hydroxamate compound, preparation method therefor and application thereof.
MX2023003264A (en) Cdk inhibitors and their use as pharmaceuticals.
MX2024008910A (en) Pharmaceutical for treating novel coronavirus infection.
EP4114458A4 (en) Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
WO2021158635A8 (en) Anti-viral compositions and methods of use
WO2022047054A3 (en) Inhibitors of sars cov-2 infection and uses thereof
EP4085131A4 (en) Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof
MX2022007336A (en) Intranasal pharmaceutical compositions of cgrp inhibitors.
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
MX2023007265A (en) Cdk inhibitors and their use as pharmaceuticals.
WO2021217120A3 (en) Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the ace2 receptor
MX2021012749A (en) Jak1 selective kinase inhibitor.
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2023012204A (en) Piperidine urea derivatives as soluble epoxide hydrolase inhibitors.
MX2022010877A (en) Bacterial strains and compositions thereof for oral use in the treatment of viral infections of the respiratory system.
BR112021019845A2 (en) Inactivated virus compositions and Zika vaccine formulations
MX2023003846A (en) Biphenyl compound as immunomodulator, preparation method therefor and application thereof.
EP4079301A3 (en) Compositions comprising cannabidiol and, optionally, bisabolol
BR112013027369A2 (en) compositions and methods
WO2008080443A3 (en) Cosmetic composition for the treatment and/or prevention of skin stretch marks

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21809656

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3179307

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21809656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021809656

Country of ref document: EP

Effective date: 20221219

ENP Entry into the national phase

Ref document number: 2021276335

Country of ref document: AU

Date of ref document: 20210518

Kind code of ref document: A